Ryvu Therapeutics SA (RVU) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.553x

Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has a cash flow conversion efficiency ratio of -0.553x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-22.84 Million ≈ $-6.29 Million USD) by net assets (zł41.33 Million ≈ $11.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RVU company net worth for the company's overall valuation and market capitalisation.

Ryvu Therapeutics SA - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Ryvu Therapeutics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Ryvu Therapeutics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ryvu Therapeutics SA ranked by their cash flow conversion efficiency. Explore Ryvu Therapeutics SA (RVU) cash flow quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
icad inc NASDAQ:ICAD	0.002x
TCM Group CO:TCM	0.087x
Bogota Financial Corp NASDAQ:BSBK	0.002x
Star Holdings NASDAQ:STHO	-0.030x
Kalray SA PA:ALKAL	0.230x
Lhyfe SA PA:LHYFE	-0.190x
Forsys Metals Corp. TO:FSY	-0.019x
DAM CAPITAL ADVISORS LTD NSE:DAMCAPITAL	0.011x

Annual Cash Flow Conversion Efficiency for Ryvu Therapeutics SA (2010–2025)

The table below shows the annual cash flow conversion efficiency of Ryvu Therapeutics SA from 2010 to 2025. View Ryvu Therapeutics SA stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	zł70.75 Million ≈ $19.47 Million	zł-110.28 Million ≈ $-30.35 Million	-1.559x	-73.22%
2024-12-31	zł143.88 Million ≈ $39.60 Million	zł-129.48 Million ≈ $-35.63 Million	-0.900x	-176.29%
2023-12-31	zł259.59 Million ≈ $71.44 Million	zł-84.55 Million ≈ $-23.27 Million	-0.326x	-624.62%
2022-12-31	zł343.39 Million ≈ $94.51 Million	zł21.32 Million ≈ $5.87 Million	0.062x	+118.18%
2021-12-31	zł169.42 Million ≈ $46.63 Million	zł-57.87 Million ≈ $-15.93 Million	-0.342x	-618.46%
2020-12-31	zł223.72 Million ≈ $61.57 Million	zł-10.64 Million ≈ $-2.93 Million	-0.048x	+67.28%
2019-12-31	zł119.76 Million ≈ $32.96 Million	zł-17.40 Million ≈ $-4.79 Million	-0.145x	+22.25%
2018-12-31	zł194.86 Million ≈ $53.63 Million	zł-36.42 Million ≈ $-10.02 Million	-0.187x	-208.91%
2017-12-31	zł64.00 Million ≈ $17.61 Million	zł10.98 Million ≈ $3.02 Million	0.172x	+252.23%
2016-12-31	zł55.71 Million ≈ $15.33 Million	zł-6.28 Million ≈ $-1.73 Million	-0.113x	+67.84%
2015-12-31	zł46.88 Million ≈ $12.90 Million	zł-16.43 Million ≈ $-4.52 Million	-0.350x	+33.84%
2014-12-31	zł9.25 Million ≈ $2.55 Million	zł-4.90 Million ≈ $-1.35 Million	-0.530x	+99.76%
2013-12-31	zł3.13 Million ≈ $861.02K	zł-694.94 Million ≈ $-191.26 Million	-222.129x	-13705.80%
2012-12-31	zł5.53 Million ≈ $1.52 Million	zł-8.90 Million ≈ $-2.45 Million	-1.609x	-208.42%
2011-12-31	zł11.46 Million ≈ $3.15 Million	zł-5.98 Million ≈ $-1.65 Million	-0.522x	+78.85%
2010-12-31	zł1.50 Million ≈ $413.48K	zł-3.71 Million ≈ $-1.02 Million	-2.467x	--

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology

Market Cap

$106.26 Million

zł386.11 Million PLN

Market Cap Rank

#19053 Global

#147 in Poland

Share Price

zł16.70

Change (1 day)

-1.65%

52-Week Range

zł13.76 - zł29.90

All Time High

zł75.00